1. Scrip
  2. >>Business
  3. >>Strategy

End of The Line Looms For Nordic Nanovector

Bankers Appointed To Explore Options

 
• By Kevin Grogan

It does not look like the Norwegian biotech can recover from the discontinuation of its lead candidate, the lymphoma drug Betalutin, and the ‘for sale’ signs are likely to be erected soon as a strategic review gets underway.

Businessman comparing two documents, neutral background
Nordic Nanovector looking at all options • Source: Archive

The failure of its lymphoma hopeful Betalutin looks like a mortal blow for Nordic Nanovector ASA and the Norway-based biotech has hired investment bank Carnegie to help explore its options.

Nordic Nanovector's woes stem from the discontinuation of the Phase IIb PARADIGME trial in July that was evaluating the anti-CD37...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business